Skip to main content
. 2010 Aug 18;249(2):183–192. doi: 10.1007/s00417-010-1470-2

Fig. 2.

Fig. 2

Box plot graphs showing the bevacizumab effect depending on the duration of the perfusion status of the macula (a, b), on the existence of pretreatment (c, d), on the patients’ age (e, f), and on the baseline visual acuity (VA) (g, h) during the 24 weeks follow-up. Left column demonstrates the course of the BCVA, the right column shows the central retinal thickness (CRT)